GlassScriptPhysician profile
Soa Yee Tsung
NPI 1992810063
$1,750.51
in general payments reported to CMS, 2019-2025
23 companies · $75.92 in 2025
The $75.92 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $170 · 2021: $95.94 · 2022: $301 · 2023: $144 · 2024: $163 · 2025: $75.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.97 | 2019-2024 | Viberzi, Linzess, Lo Loestrin Fe |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.78 | 2019-2024 | Xifaxan |
| Therapeuticsmd, INC. | $128.53 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $126.58 | 2019-2023 | Ingrezza |
| Mylan Specialty L.P. | $113.89 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $107.86 | 2019-2020 | |
| Bausch Health US, LLC | $103.80 | 2019-2020 | |
| Pfizer INC. | $95.54 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.93 | 2022 | |
| Ardelyx, INC. | $57.26 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $55.93 | 2019-2022 | |
| Allergan, INC. | $49.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $45.67 | 2019-2023 | Breztri |
| Alfasigma USA, INC. | $44.43 | 2020-2022 | |
| Sanofi Pasteur INC. | $39.57 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $28.10 | 2024 | Rybelsus, Ozempic |
| Amgen INC. | $23.53 | 2019 | |
| Ibsa Pharma INC. | $22.92 | 2020 | |
| Vertical Pharmaceuticals, LLC | $22.64 | 2019 | |
| Daiichi Sankyo INC. | $21.19 | 2019 | |
| Viatris Specialty LLC | $18.66 | 2025 | Yupelri |
| Horizon Therapeutics Plc | $16.09 | 2019 | |
| Shionogi INC | $15.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soa Tsung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.